Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Protagonist price target raised to $50 from $36 at H.C. Wainwright » 07:09
06/18/21
06/18
07:09
06/18/21
07:09
PTGX

Protagonist Therapeutics

$43.13 /

+1.54 (+3.70%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Protagonist Therapeutics to $50 from $36 and reiterates a Buy rating on the shares citing the "strong" rusfertide data from the ongoing polycythemia vera Phase 2 study. The analyst increased the probability of success of rusfertide to 50% and built out a European model.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$43.13 /

+1.54 (+3.70%)

PTGX Protagonist Therapeutics
$43.13 /

+1.54 (+3.70%)

06/14/21 Northland
Protagonist Therapeutics price target raised to $47 from $42 at Northland
05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
PTGX Protagonist Therapeutics
$43.13 /

+1.54 (+3.70%)

  • 16
    Jun
  • 11
    Dec
Syndicate
Protagonist Therapeutics 3.05M share Spot Secondary priced at $37.75 » 21:11
06/15/21
06/15
21:11
06/15/21
21:11
PTGX

Protagonist Therapeutics

$38.18 /

-2.96 (-7.19%)

The deal size was…

The deal size was increased to $3.05M shares from 2.4M and priced below last closing price of $38.15. JPMorgan, Jefferies and Piper Sandler are acting as joint book running managers for the offering.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$38.18 /

-2.96 (-7.19%)

PTGX Protagonist Therapeutics
$38.18 /

-2.96 (-7.19%)

06/14/21 Northland
Protagonist Therapeutics price target raised to $47 from $42 at Northland
05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
PTGX Protagonist Therapeutics
$38.18 /

-2.96 (-7.19%)

  • 16
    Jun
  • 11
    Dec
Syndicate
Protagonist Therapeutics announces $100M common stock offering » 17:01
06/14/21
06/14
17:01
06/14/21
17:01
PTGX

Protagonist Therapeutics

$41.14 /

+1.44 (+3.63%)

Protagonist Therapeutics…

Protagonist Therapeutics announced that it has commenced an underwritten public offering of $100M of shares of its common stock. J.P. Morgan Securities, Jefferies and Piper Sandler are acting as joint book-running managers for the offering. JMP Securities and H.C. Wainwright & Co. are acting as co-lead managers for the offering.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$41.14 /

+1.44 (+3.63%)

PTGX Protagonist Therapeutics
$41.14 /

+1.44 (+3.63%)

06/14/21 Northland
Protagonist Therapeutics price target raised to $47 from $42 at Northland
05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
PTGX Protagonist Therapeutics
$41.14 /

+1.44 (+3.63%)

  • 11
    Dec
Recommendations
Protagonist Therapeutics price target raised to $47 from $42 at Northland » 07:52
06/14/21
06/14
07:52
06/14/21
07:52
PTGX

Protagonist Therapeutics

$39.59 /

+5.67 (+16.72%)

Northland analyst Tim…

Northland analyst Tim Chiang raised the firm's price target on Protagonist Therapeutics to $47 from $42 and reiterates an Outperform rating on the shares following the release of additional data on rusfertide. The Phase 2 study in polycythemia vera patients which showed sustained hematocrit control and a reduction in phlebotomies for up to 18 months, Chiang tells investors in a research note.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$39.59 /

+5.67 (+16.72%)

PTGX Protagonist Therapeutics
$39.59 /

+5.67 (+16.72%)

05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
PTGX Protagonist Therapeutics
$39.59 /

+5.67 (+16.72%)

  • 11
    Dec
Conference/Events
Protagonist Therapeutics to host conference call » 07:45
06/11/21
06/11
07:45
06/11/21
07:45
PTGX

Protagonist Therapeutics

$33.86 /

-1.5 (-4.24%)

Management discusses…

Management discusses updated Phase 2 Rusfertide results in Polycythemia Vera as presented at EHA 2021 on a conference call to be held on June 11 at 8 am. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

  • 11
    Dec
Hot Stocks
Protagonist Therapeutics updates results from Phase 2 study of rusfertide » 07:05
06/11/21
06/11
07:05
06/11/21
07:05
PTGX

Protagonist Therapeutics

$33.86 /

-1.5 (-4.24%)

Protagonist Therapeutics…

Protagonist Therapeutics announced updated results from the ongoing Phase 2 study of rusfertide, an investigational new drug being evaluated for the treatment of polycythemia vera. These data were presented in an oral presentation today at the European Hematology Association 2021 Virtual Congress. "This data set cumulatively builds on previously presented scientific evidence demonstrating rusfertide's potential as the first-in-class, non-cytoreductive treatment option for polycythemia vera, a disease that currently has limited therapeutic options and a demonstrated significant unmet medical need," said Dinesh Patel, Ph.D., President and CEO of Protagonist. "The possibility of advancing PV treatment beyond the current standard of care is compelling to patients and the medical community. The durability of effect and symptom improvements being observed in our fully enrolled Phase 2 study, along with the recent Breakthrough Therapy Designation from the FDA, provides further support for the advancement of rusfertide into Phase 3 clinical development in early 2022." Summary of Results: Therapeutic phlebotomies were essentially eliminated and a target hematocrit of less than 45% was maintained for the vast majority of patients treated with rusfertide. Rusfertide demonstrated long-term control of hematocrit, as well as durability of effect based on patients treated up to 18 months. Rusfertide treatment also led to reversal of iron deficiency as evidenced by increasing serum ferritin, mean corpuscular volume and mean corpuscular hemoglobin values. Rusfertide demonstrated similar efficacy in all patients, independent of risk group or prior and concurrent therapy. Benefits were observed in patient reported outcomes, as shown by improvement in PGI-C and reduction in MPN-SAF Symptom Scores, attributed largely to the sub-scores of fatigue and concentration, consistent with improvement in iron deficiency. The current data indicate that rusfertide is well tolerated. The most common adverse events observed were transient injection site reactions.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

  • 11
    Dec
Conference/Events
Protagonist Therapeutics to host conference call » 04:55
06/11/21
06/11
04:55
06/11/21
04:55
PTGX

Protagonist Therapeutics

$33.86 /

-1.5 (-4.24%)

Management discusses…

Management discusses updated Phase 2 Rusfertide results in Polycythemia Vera as presented at EHA 2021 on a conference call to be held on June 11 at 8 am. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

  • 11
    Dec
Conference/Events
Protagonist Therapeutics to host conference call » 16:26
06/10/21
06/10
16:26
06/10/21
16:26
PTGX

Protagonist Therapeutics

$33.86 /

-1.5 (-4.24%)

Management discusses…

Management discusses updated Phase 2 Rusfertide results in Polycythemia Vera as presented at EHA 2021 on a conference call to be held on June 11 at 8 am. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
PTGX Protagonist Therapeutics
$33.86 /

-1.5 (-4.24%)

  • 11
    Dec
Hot Stocks
Protagonist Therapeutics receives FDA BTD for rusfertide » 07:08
06/03/21
06/03
07:08
06/03/21
07:08
PTGX

Protagonist Therapeutics

$34.51 /

+0.43 (+1.26%)

Protagonist Therapeutics…

Protagonist Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera for the reduction of erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leukocytosis.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$34.51 /

+0.43 (+1.26%)

PTGX Protagonist Therapeutics
$34.51 /

+0.43 (+1.26%)

05/24/21 Northland
Protagonist Therapeutics initiated with an Outperform at Northland
05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
PTGX Protagonist Therapeutics
$34.51 /

+0.43 (+1.26%)

  • 11
    Dec
Initiation
Protagonist Therapeutics initiated with an Outperform at Northland » 07:34
05/24/21
05/24
07:34
05/24/21
07:34
PTGX

Protagonist Therapeutics

$34.30 /

+1.37 (+4.16%)

Northland analyst Tim…

Northland analyst Tim Chiang initiated coverage of Protagonist Therapeutics with an Outperform rating and $42 price target. The company's lead candidate, rusfertide, has the potential to be a "game changing treatment" for polycythemia vera, a rare blood disorder that impacts about 100,000 patients in the U.S., Chiang tells investors. Possible approval of rusfertide is still about three years away, but he think there is potential for about $1.5B in peak annual sales, Chiang said.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$34.30 /

+1.37 (+4.16%)

PTGX Protagonist Therapeutics
$34.30 /

+1.37 (+4.16%)

05/12/21 Piper Sandler
Piper says Protagonist Therapeutics' EHA abstract includes 'spectacular' data
03/11/21 H.C. Wainwright
Protagonist Therapeutics price target raised to $36 from $33 at H.C. Wainwright
03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
01/06/21 JPMorgan
Protagonist Therapeutics initiated with an Overweight at JPMorgan
PTGX Protagonist Therapeutics
$34.30 /

+1.37 (+4.16%)

  • 11
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.